Bevacizumab plus irinotecan in recurrent glioblastoma - Reply

被引：4
|
作者：
Vredenburgh, James J. [1 ]
Desjardins, Annick
Reardon, David A.
Friedman, Henry S.
机构：
[1] Duke Univ, Med Ctr, Preston Robert Tisch Brain Tumor Ctr, Durham, NC 27710 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 06期
关键词：
D O I：
10.1200/JCO.2007.15.1746
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1013 / 1013
页数：1
相关论文
共 50 条
  • [11] BEVACIZUMAB ALONE VERSUS BEVACIZUMAB PLUS IRINOTECAN IN PATIENTS WITH RECURRENT GLIOBLASTOMA: A NATIONWIDE POPULATION-BASED STUDY
    Lee, Yeonhu
    Roh, Tae Hoon
    Kim, Se-Hyuk
    NEURO-ONCOLOGY, 2023, 25
  • [12] BEVACIZUMAB ALONE VERSUS BEVACIZUMAB PLUS IRINOTECAN IN PATIENTS WITH RECURRENT GLIOBLASTOMA: A NATIONWIDE POPULATION-BASED STUDY
    Lee, Yeonhu
    Roh, Tae Hoon
    Kim, Se-Hyuk
    NEURO-ONCOLOGY, 2023, 25
  • [13] Bevacizumab in combination with irinotecan for patients with recurrent glioblastoma multiforme
    Schiff, David
    Purow, Benjamin
    NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (04): : 186 - 187
  • [14] Bevacizumab in combination with irinotecan for patients with recurrent glioblastoma multiforme
    David Schiff
    Benjamin Purow
    Nature Clinical Practice Oncology, 2008, 5 : 186 - 187
  • [15] Bevacizumab and irinotecan in patients with recurrent glioblastoma multiforme (GBM)
    Raval, Sumul N.
    Rule, Amy
    Hwang, Shirley S.
    NEURO-ONCOLOGY, 2006, 8 (04) : 482 - 482
  • [16] Neutrophil-to-lymphocyte ratio is prognostic in recurrent glioblastoma multiforme treated with bevacizumab plus irinotecan
    Haksoyler, Veysel
    A Besen, Ali
    Koseci, Tolga
    Olgun, Polat
    Bayram, Ertugrul
    Topkan, Erkan
    BIOMARKERS IN MEDICINE, 2021, 15 (11) : 851 - 859
  • [17] Letter to the Editor: Commentary on "Bevacizumab Alone Versus Bevacizumab Plus Irinotecan in Patients With Recurrent Glioblastoma" Authors' Response to the Letter
    Lee, Yeonhu
    Lee, Eunyoung
    Roh, Tae Hoon
    Kim, Se-Hyuk
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2024, 39 (41)
  • [18] Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
    Kreisl, Teri N.
    Kim, Lyndon
    Moore, Kraig
    Duic, Paul
    Royce, Cheryl
    Stroud, Irene
    Garren, Nancy
    Mackey, Megan
    Butman, John A.
    Camphausen, Kevin
    Park, John
    Albert, Paul S.
    Fine, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) : 740 - 745
  • [19] Bevacizumab plus irinotecan in treatment of recurrent brain gliomas
    Stec, Rafal
    Bodnar, Lubomir
    Smoter, Marta
    Szczylik, Cezary
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2010, 14 (04): : 253 - 258
  • [20] Bevacizumab and irinotecan in patients (pts) with recurrent glioblastoma multiforme (GBM)
    Raval, S.
    Hwang, S.
    Dorsett, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345